Detection of Aberrant p16 Methylation in Blood of Hepatocellular Carcinoma Patients

Dina Tharwat Abd Elfattah Mohammed;

Abstract


H
epatocellular carcinoma (HCC) is one of the most common malignancies worldwide and it is one of the major causes of death, because of its high frequency and poor prognosis. Conventional tests of hepatic function don't distinguish HCC from other hepatic masses or from cirrhosis. Accordingly, they poorly contribute to the diagnosis of the tumor. Diagnosis of HCC depends mainly on the detection of tumor markers in the sera of the HCC patients in addition to other diagnostic modalities such as ultrasound, spiral CT and liver histopathology.
Serum AFP concentrations have been shown to be the most useful tumor marker with regards to HCC ,but it may be normal in up to 40% of patients. Also it may be increased in chronic hepatitis and cirrhotic patients. The availability of a more sensitive serological marker that permits earlier diagnosis and risk assessment in high risk populations will be very useful for better management of HCC.
Changes in status of DNA methylation are among the most common molecular alterations in human neoplasia. Several studies have suggested that promoter CpG islands o


Other data

Title Detection of Aberrant p16 Methylation in Blood of Hepatocellular Carcinoma Patients
Other Titles الكشف عن المثيله الشاذه لجين p16 في الدم لمرضى سرطان الخلايا الكبديه
Authors Dina Tharwat Abd Elfattah Mohammed
Issue Date 2017

Attached Files

File SizeFormat
J3059.pdf360.01 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

views 1 in Shams Scholar
downloads 1 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.